安罗替尼联合复方斑蝥胶囊治疗不耐受化疗的驱动基因阴性晚期NSCLC合并COPD的效果

Effect of Anlotinib Combined with Compound Banmao Capsules in the Treatment of Chemotherapy Intolerance and Driver Gene Negative of Advanced NSCLC Complicated with COPD

目的:探讨安罗替尼联合复方斑蝥胶囊治疗不耐受化疗的驱动基因阴性晚期非小细胞肺癌(NSCLC)合并慢性阻塞性肺疾病(COPD)的效果。方法:选取2021年10月—2022年12月抚州市第一人民医院收治的48例不耐受化疗的驱动基因阴性晚期NSCLC合并COPD患者,按随机数字表法分为试验组和对照组,每组24例。对照组采用复方斑蝥胶囊治疗,试验组在对照组的基础上采用安罗替尼治疗,两组均治疗2个疗程。比较两组近期疗效、细胞生长相关因子[血管内皮细胞生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)]、肿瘤标志物[鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、细胞角蛋白19片段(Cyfra21-1)]、生活质量及不良反应发生情况。结果:试验组疾病控制率高于对照组,治疗后VEGF、MMP-9、SCCA、CEA、Cyfra21-1水平均低于对照组,生活质量优于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:安罗替尼联合复方斑蝥胶囊治疗不耐受化疗驱动基因阴性晚期NSCLC合并COPD患者的安全性较高,且能降低肿瘤标志物水平,改善生活质量,增强治疗效果。

Objective:To investigate the effect of Anlotinib combined with Compound Banmao Capsules in the treatment of chemotherapy intolerance and driver gene negative of advanced non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary diseases(COPD).Method:A total of 48 patients with chemotherapy intolerance and driver gene negative of advanced NSCLC complicated with COPD treated in First People's Hospital of Fuzhou from October 2021 to December 2022 were selected and divided into experimental group and control group according to random number table method,with 24 cases in each group.The control group was treated with Compound Banmao Capsules,and the experimental group was treated with Anlotinib on the basis of the control group,both groups were treated for 2 courses.The short-term effect,cell growth related factors[vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9)],tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),cytokeratin 19 fragment(Cyfra21-1)],quality of life and occurrence of adverse reactions were compared between the two groups.Result:The disease control rate of experimental group was higher than that of control group,the levels of VEGF,MMP-9,SCCA,CEA and Cyfra21-1 of experimental group after treatment were lower than those of control group,and the quality of life of experimental group was better than that of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anlotinib combined with Compound Banmao Capsules has high safety in the treatment of chemotherapy intolerance and driver gene negative of advanced NSCLC complicated with COPD,and can reduce the level of tumor markers,improve the quality of life and enhance the therapeutic effect.